158 related articles for article (PubMed ID: 25872121)
1. Simultaneous targeting of multiple opioid receptor types.
Bird MF; Lambert DG
Curr Opin Support Palliat Care; 2015 Jun; 9(2):98-102. PubMed ID: 25872121
[TBL] [Abstract][Full Text] [Related]
2. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
3. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile.
Dietis N; Guerrini R; Calo G; Salvadori S; Rowbotham DJ; Lambert DG
Br J Anaesth; 2009 Jul; 103(1):38-49. PubMed ID: 19474215
[TBL] [Abstract][Full Text] [Related]
5. Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand.
Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
Life Sci; 2012 Jun; 90(25-26):957-61. PubMed ID: 22580287
[TBL] [Abstract][Full Text] [Related]
6. The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures.
Parenti C; Turnaturi R; Aricò G; Gramowski-Voss A; Schroeder OH; Marrazzo A; Prezzavento O; Ronsisvalle S; Scoto GM; Ronsisvalle G; Pasquinucci L
Neuropharmacology; 2013 Aug; 71():70-82. PubMed ID: 23541722
[TBL] [Abstract][Full Text] [Related]
7. Hot topics in opioid pharmacology: mixed and biased opioids.
Azzam AAH; McDonald J; Lambert DG
Br J Anaesth; 2019 Jun; 122(6):e136-e145. PubMed ID: 31010646
[TBL] [Abstract][Full Text] [Related]
8. Implication of delta opioid receptor subtype 2 but not delta opioid receptor subtype 1 in the development of morphine analgesic tolerance in a rat model of chronic inflammatory pain.
Beaudry H; Gendron L; Morón JA
Eur J Neurosci; 2015 Apr; 41(7):901--7. PubMed ID: 25639561
[TBL] [Abstract][Full Text] [Related]
9. Selectivity profiling of NOP, MOP, DOP and KOP receptor antagonists in the rat spinal nerve ligation model of mononeuropathic pain.
Rutten K; Schröder W; Christoph T; Koch T; Tzschentke TM
Eur J Pharmacol; 2018 May; 827():41-48. PubMed ID: 29524385
[TBL] [Abstract][Full Text] [Related]
10. Multitargeted Opioid Ligand Discovery as a Strategy to Retain Analgesia and Reduce Opioid-Related Adverse Effects.
Smith MT; Kong D; Kuo A; Imam MZ; Williams CM
J Med Chem; 2023 Mar; 66(6):3746-3784. PubMed ID: 36856340
[TBL] [Abstract][Full Text] [Related]
11. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands.
Bird MF; Vardanyan RS; Hruby VJ; Calò G; Guerrini R; Salvadori S; Trapella C; McDonald J; Rowbotham DJ; Lambert DG
Br J Anaesth; 2015 Apr; 114(4):646-56. PubMed ID: 25680364
[TBL] [Abstract][Full Text] [Related]
12. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
13. Remifentanil produces cross-desensitization and tolerance with morphine on the mu-opioid receptor.
Nowoczyn M; Marie N; Coulbault L; Hervault M; Davis A; Hanouz JL; Allouche S
Neuropharmacology; 2013 Oct; 73():368-79. PubMed ID: 23792280
[TBL] [Abstract][Full Text] [Related]
14. The plasticity of the association between mu-opioid receptor and glutamate ionotropic receptor N in opioid analgesic tolerance and neuropathic pain.
Sánchez-Blázquez P; Rodríguez-Muñoz M; Berrocoso E; Garzón J
Eur J Pharmacol; 2013 Sep; 716(1-3):94-105. PubMed ID: 23499699
[TBL] [Abstract][Full Text] [Related]
15. CYX-5, a G-protein biassed MOP receptor agonist, DOP receptor antagonist and KOP receptor agonist, evokes constipation but not respiratory depression relative to morphine in rats.
Imam MZ; Kuo A; Ghassabian S; Cai Y; Qin Y; Li T; Smith MT
Pharmacol Rep; 2023 Jun; 75(3):634-646. PubMed ID: 36637684
[TBL] [Abstract][Full Text] [Related]
16. Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance.
Zhang X; Bao L; Guan JS
Trends Pharmacol Sci; 2006 Jun; 27(6):324-9. PubMed ID: 16678916
[TBL] [Abstract][Full Text] [Related]
17. Heteromers of μ-δ opioid receptors: new pharmacology and novel therapeutic possibilities.
Fujita W; Gomes I; Devi LA
Br J Pharmacol; 2015 Jan; 172(2):375-87. PubMed ID: 24571499
[TBL] [Abstract][Full Text] [Related]
18. Exploiting the Power of Stereochemistry in Drug Action: 3-[(2
Turnaturi R; Pasquinucci L; Chiechio S; Grasso M; Marrazzo A; Amata E; Dichiara M; Prezzavento O; Parenti C
ACS Chem Neurosci; 2020 Apr; 11(7):999-1005. PubMed ID: 32186844
[TBL] [Abstract][Full Text] [Related]
19. In vitro profiling of opioid ligands using the cAMP formation inhibition assay and the β-arrestin2 recruitment assay: No two ligands have the same profile.
Kuo A; Magiera J; Rethwan N; Andersson Å; Leen Lam A; Wyse B; Meutermans W; Lewis R; Smith M
Eur J Pharmacol; 2020 Apr; 872():172947. PubMed ID: 31991138
[TBL] [Abstract][Full Text] [Related]
20. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC
Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
